Company Profile
REGENXBIO Inc. Stock Price, News & Analysis
- Ticker:
- RGNX
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
11.28 USD (+7.43%)
Close
Last updated: August 6, 2026
337M USD
Market cap
Why the stock is moving
As of Aug 6, 2026, RGNX closed up 7.43% at $11.28. No new same-company headline was identified in the current news window.
Company overview
Business overview
REGENXBIO is a gene-therapy company focused on adeno-associated virus platform programs and rare diseases. Its story is built around platform delivery and the commercialization of gene-based medicines.
Geographic Base and Sector Classification
Headquartered in the United States and listed on NASDAQ, REGENXBIO sits in gene therapy.
Business Model Characteristics
The company depends on clinical validation, manufacturing execution, and the ability to create durable gene-therapy value.
Position Within the Biotechnology Landscape
REGENXBIO is a high-catalyst gene-therapy name whose valuation is tied to platform and clinical progress.
Future catalysts
REGENXBIO's catalysts are its ocular gene-therapy programs and the broader rare-disease pipeline, with the market wanting proof the platform still has staying power. The next update matters if it shows the gene-therapy franchise can keep advancing.
Recent news
- 01
REGENXBIO to Participate in Upcoming Investor Conferences
Source: REGENXBIO Inc.
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of REGENXBIO Inc. (RGNX)?
REGENXBIO Inc. (RGNX) most recently closed at 11.28 USD, a +7.43% move versus the previous session.
What is the market cap of REGENXBIO Inc. (RGNX)?
REGENXBIO Inc. currently has a market capitalization of 337M USD on BioPharmSignal.
What does REGENXBIO Inc. do?
REGENXBIO is a gene-therapy company focused on adeno-associated virus platform programs and rare diseases. Its story is built around platform delivery and the commercialization of gene-based medicines.
On which exchange is RGNX stock listed?
REGENXBIO Inc. (RGNX) is associated with NASDAQ, United States, Biopharma.
Which therapeutic areas is REGENXBIO Inc. focused on?
REGENXBIO Inc. is associated with rare disease based on its company overview and current catalyst commentary.
What future catalysts are investors watching for REGENXBIO Inc.?
REGENXBIO's catalysts are its ocular gene-therapy programs and the broader rare-disease pipeline, with the market wanting proof the platform still has staying power. The next update matters if it shows the gene-therapy franchise can keep advancing.